A comparative study of microneedle-based cutaneous immunization with other conventional routes to assess feasibility of microneedles for allergy immunotherapy

Vaccine

Volumn 33, Issue 33, 2015, Pages 4060-4064

  Shakya, Akhilesh Kumar ^a   Gill, Harvinder Singh ^a  

^a Texas Tech University   (United States)

Author keywords

Allergen specific immunotherapy; Microneedles; Ovalbumin; Subcutaneous immunotherapy

Indexed keywords

ALLERGEN; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 5; OVALBUMIN; CYTOKINE; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; FLUORESCENCE MICROSCOPY; IMMUNIZATION; MICRONEEDLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SUBCUTANEOUS IMMUNOTHERAPY; TH1 CELL; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; HYPERSENSITIVITY; IMMUNOLOGY; IMMUNOTHERAPY; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; PROCEDURES;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ALLERGENS; ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; HYPERSENSITIVITY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOTHERAPY; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAPERITONEAL; MICE, INBRED BALB C; OVALBUMIN; TH1 CELLS;

EID: 84952636608     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.06.042     Document Type: Article

References (21)

1. Cox L., Nelson H., Lockey R., Calabria C., Chacko T., Finegold I., et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011, 127(January (Suppl. 1)):S1-S55.
2. von Moos S., Kundig T.M., Senti G. Novel administration routes for allergen-specific immunotherapy: a review of intralymphatic and epicutaneous allergen-specific immunotherapy. Immunol Allergy Clin N Am 2011, 31(May (2)):391-406. xi.
3. Senti G., von Moos S., Tay F., Graf N., Sonderegger T., Johansen P., et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol 2012, 129(January (1)):128-135.
4. Birchall J.C., Clemo R., Anstey A., John D.N. Microneedles in clinical practice - an exploratory study into the opinions of healthcare professionals and the public. Pharm Res 2011, 28(January (1)):95-106.
5. Lee J.W., Han M.R., Park J.H. Polymer microneedles for transdermal drug delivery. J Drug Target 2012, (November).
6. Gill H.S., Denson D.D., Burris B.A., Prausnitz M.R. Effect of microneedle design on pain in human volunteers. Clin J Pain 2008, 24(September (7)):585-594.
7. Carey J.B., Vrdoljak A., O'Mahony C., Hill A.V., Draper S.J., Moore A.C. Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route. Sci Rep 2014, 4:6154.
8. Song J.M., Kim Y.C., Lipatov A.S., Pearton M., Davis C.T., Yoo D.G., et al. Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B- and T-cell responses in mice. Clin Vaccine Immunol 2010, 17(September (9)):1381-1389.
9. van der Maaden K., Trietsch S.J., Kraan H., Varypataki E.M., Romeijn S., Zwier R., et al. Novel hollow microneedle technology for depth-controlled microinjection-mediated dermal vaccination: a study with polio vaccine in rats. Pharm Res 2014, 31(July (7)):1846-1854.
10. Vissers J.L., van Esch B.C., Hofman G.A., Kapsenberg M.L., Weller F.R., van Oosterhout A.J. Allergen immunotherapy induces a suppressive memory response mediated by IL-10 in a mouse asthma model. J Allergy Clin Immunol 2004, 113(June (6)):1204-1210.
11. Widera G., Johnson J., Kim L., Libiran L., Nyam K., Daddona P.E., et al. Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system. Vaccine 2006, 24(March (10)):1653-1664.
12. von Moos S., Johansen P., Waeckerle-Men Y., Mohanan D., Senti G., Haffner A., et al. The contact sensitizer diphenylcyclopropenone has adjuvant properties in mice and potential application in epicutaneous immunotherapy. Allergy 2012, 67(May (5)):638-646.
13. Gupta J., Gill H.S., Andrews S.N., Prausnitz M.R. Kinetics of skin resealing after insertion of microneedles in human subjects. J Control Release 2011, 154(September (2)):148-155.
14. Fehres C.M., Garcia-Vallejo J.J., Unger W.W., van Kooyk Y. Skin-resident antigen-presenting cells: instruction manual for vaccine development. Front Immunol 2013, 4:157.
15. Van Oosterhout A.J., Van Esch B., Hofman G., Hofstra C.L., Van Ark I., Nijkamp F.P., et al. Allergen immunotherapy inhibits airway eosinophilia and hyperresponsiveness associated with decreased IL-4 production by lymphocytes in a murine model of allergic asthma. Am J Respir Cell Mol Biol 1998, 19(October (4)):622-628.
16. Kouro T., Takatsu K. IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol 2009, 21(December (12)):1303-1309.
17. Davoodi P., Mahesh P.A., Holla A.D., Vijayakumar G.S., Jayaraj B.S., Chandrashekara S., et al. Serum levels of interleukin-13 and interferon-gamma from adult patients with asthma in Mysore. Cytokine 2012, 60(November (2)):431-437.
18. Kabesch M., Schedel M., Carr D., Woitsch B., Fritzsch C., Weiland S.K., et al. IL-4/IL-13 pathway genetics strongly influence serum IgE levels and childhood asthma. J Allergy Clin Immunol 2006, 117(February (2)):269-274.
19. ten Hacken N.H., Oosterhoff Y., Kauffman H.F., Guevarra L., Satoh T., Tollerud D.J., et al. Elevated serum interferon-gamma in atopic asthma correlates with increased airways responsiveness and circadian peak expiratory flow variation. Eur Respir J 1998, 11(February (2)):312-316.
20. Nials A.T., Uddin S. Mouse models of allergic asthma: acute and chronic allergen challenge. Dis Model Mech 2008, 1(November-December (4-5)):213-220.
21. Franchi L., Nunez G. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur J Immunol 2008, 38(August (8)):2085-2089.